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1. Introduction  
Crohn’s disease (CD) is a chronic gastrointestinal disorder which, together with ulcerative 
colitis, is known as Inflammatory Bowel Disease (IBD). CD is characterized by transmural 
inflammation of the entire gastrointestinal tract, from oral cavity to anus. The most common 
symptoms are chronic diarrhea and abdominal pain, which are often accompanied by 
anorexia, malaise, weight loss, fever and extra-intestinal manifestations. The latter can 
involve almost every organ system (Macfarlane et al., 2009). CD can cause the formation of 
strictures, abscesses or fistulas. For that reason, surgical resection in CD patients is very 
common.  
Regardless of the vast amount of data gathered on the etiology and the course of CD, the 
actual cause is still unknown. The interplay of various factors is blamed for the disease 
outbreak. These factors include genetic predisposition, environmental influences (e.g. 
smoking), imbalance in immune response and changes in intestinal flora. Given the 
complexity of the disease, some factors may be the consequence of others.  
Genetic predisposition has received the most research attention in recent years. Family 
studies have shown that more than 50% concordance of CD can be expected in monozygotic 
twins. These findings indicate that the pathogenesis of CD is not based only on one gene but 
on a polygenic risk profile (Vavricka & Rogler, 2009). In 2001, two independent groups of 
researchers discovered one of the most important susceptibility genes for CD, a gene for 
NOD2/CARD15 (Hugot et al., 2001; Ogura et al., 2001). Its mutation is present in about one 
third of all CD patients. Patients with mutated NOD2/CARD15 variants could have a 
deficient response to bacterial LPS which could lead to the development of CD (Ogura et al., 
2001). Several other genes that can contribute to susceptibility to CD have been identified. 
These include IBD5, IL23R, ATG16L1, Chr5p13.1, Chr5q33.1 and Chr10q21.1 (Xavier & 
Podolsky, 2007). They are involved in the maintenance of barrier function and regulation of 
innate and adaptive immunity. 
There are several environmental factors that have been predicted to be involved in the 
development of CD. The single most important environmental risk factor for the 
development of CD is tobacco smoking. Further environmental risk factors are related to 
living in urban areas of developed western countries with stressful lifestyle. There is also 
some evidence that diet could influence the risk for CD. Uptake of fatty acids and sugar, 
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which has increased in the last decades in developed countries, has been linked to an 
increase in the incidence of CD (Hanauer, 2006).  
Dysregulated immune response and exaggerated response to exogenous factors, including 
the intestinal microbiota, is also an important contributor to CD. Immune response at the 
intestinal mucosa is mediated by epithelial and mucosal immune cells. They recognize 
molecules of bacterial origin via Toll-like and NOD-like receptors. Receptor binding leads to 
activation of the NF-κB pathway, which is a crucial regulator of the inflammatory response. 
In epithelial Paneth cells, NF-κB activation leads to the production of defensins. In antigen 
presenting cells, activation of NF-κB leads, with the involvement of procaspase 1, to the 
production of proinflammatory cytokines, which stimulate further inflammation events 
(Xavier & Podolsky, 2007). Increased expression of Th1 cytokines, mainly IFNǄ, IL-12, 
TNFǂ, IL-1ǃ and IL-6, has been considered fundamental in maintaining the inflammation. 
Other cytokines, such as IL-8, IL-18 and IL-23 have also been involved (Dharmani & Chadee, 
2008). 
Even though the actual role of bacteria in the pathogenesis of CD is still unknown, the 
differences in the composition of intestinal flora between healthy individuals and CD 
patients are today a well established fact. They have recently been confirmed by the 
metagenomic sequencing of the intestinal microbiome (Manichanh et al., 2006; Qin et al., 
2010). The difference is characterized by the reduction of species diversity from the phylum 
Firmicutes and an increase in the concentration of enterobacteriaceae, especially Escherichia 
coli. Interestingly, no significant differences in flora composition were observed between 
inflamed and non-inflamed intestinal mucosa of CD patients (Vasquez et al., 2007). CD is 
often associated with the presence of specific microorganisms (adherent and invasive E. coli, 
Mycobacterium avium subsp. paratuberculosis; described below) and lack of others 
(Faecalibacterium prausnitzii). F. prausnitzii is a member of Firmicutes which has been observed 
to be present in lower quantities in patients with endoscopic recurrence of CD six months 
after the surgery, in comparison to patients that were still in remission after surgery. Anti-
inflammatory effects of F. prausnitzii have been demonstrated in in vitro and in vivo mouse 
models (Sokol et al., 2008). Taken together, it has been hypothesized that either a single 
pathogen, increased mucosal permeability, or imbalance between “good” and “bad” 
bacteria (dysbiosis) contribute to the CD onset. 
The hypothesis of a single pathogen is based on the assumption that M. avium subsp. 
paratuberculosis (MAP) could be the causative agent of CD, and has been supported by a 
considerable body of evidence. Investigators were able to isolate MAP from the inflamed 
tissue and peripheral blood of CD patients, detect anti-MAP antibodies and also prove its 
presence using molecular analysis (De Hertogh et al., 2008; Macfarlane et al., 2009). 
However, this was not enough to prove MAP as causative agent of CD, especially since 
treatment with drugs against MAP had no effect on the improvement of CD. Several other 
bacteria have also been associated with CD pathogenesis. These include Listeria 
monocytogenes, Pseudomonas maltophilia, M. kansasii, Bacteroides fragilis and adherent invasive 
E. coli (AIEC) (De Hertogh et al., 2008; Macfarlane et al., 2009). The latter is a specific 
pathovar that has been shown to colonize intestinal mucosa of 36.4% of patients with ileal 
CD. It is able to replicate in macrophages and cause the release of large amounts of TNFǂ 
(Rolhion & Darfeuille-Michaud, 2007). There is also evidence that AIEC plays an important 
role in the formation of granulomas which are a histological characteristic of CD. 
Colonization with AIEC was recently linked to the previously mentioned NOD2/CARD15 
mutation, (Barnich & Darfeuille-Michaud, 2007; Rolhion & Darfeuille-Michaud, 2007).  
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A second hypothesis is based on an increased permeability of intestinal mucosa which can 
cause translocation of bacteria and their metabolites from the gastrointestinal tract to 
mesenteric lymph nodes and other internal organs (De Hertogh et al., 2008). Occurrence of 
such bacterial translocation in patients with CD after surgery has been documented and has 
caused systemic inflammatory septic response. E. coli, Enteroccoccus ssp, Bact. fragilis, and 
Klebsiella pneumoniae were among the bacterial species which translocated to the greatest 
extent (Takesue et al., 2002). 
A third, dysbiosis theory suggests a broken equilibrium between “good” and “bad” 
intestinal bacteria as a cause of CD (Tamboli et al., 2004). The hypothesis is based on a 
number of studies of faecal and mucosal associated microflora which were found to differ 
between CD patients and healthy individuals (reviewed by Tamboli et al., (2004)). The data 
obtained with classic bacteriological culturing techniques was recently substantiated by 
metagenomic sequencing (Qin et al., 2010). Faecal microflora from patients with CD contains 
decreased numbers of butyrate producing Firmicutes, especially the Clostridium leptum group 
(Manichanh et al., 2006). Ribosomal DNA sequence analysis of mucosa associated bacteria in 
patients with CD has shown increased levels of facultative bacteria (e. g. E. coli) in colonic 
mucosa. In small intestinal mucosa, decreased levels of C. leptum and Prevotella nigrescens 
subgroups were observed, as well as increased level of the Ruminococcus gnavus subgroup 
(Prindiville et al., 2006). These results speak in favor of the dysbiosis theory and make the 
single pathogen theory less likely.  
The aim of this chapter is to introduce ways of interference with the diversity and 
abundance of intestinal bacteria, which are important in CD pathogenesis. Clinical efficacy 
of various strategies will also be presented. 
2. Probiotics 
The Food and Agriculture Organization and the World Health Organization have defined 
probiotics as “live microorganisms which, when administrated in adequate amounts as part 
of food, confer a health benefit on the host”. Probiotics usually belong to the genera 
Lactobacillus or Bifidobacterium. These are gram positive bacteria with fermentative 
metabolism, in which lactic acid is a major product. They are obligatory or facultative 
anaerobes and are non-motile. Among lactobacilli, strains with probiotic properties are Lb. 
acidophilus, including strain LA-5, Lb. crispatus, Lb. johnsonii LA1, Lb. gasseri PA16, Lb. casei, 
Lb. paracasei, strains “shirota” and “defensis”, Lb. rhamnosus GG, Lb. reuteri and Lb. plantarum. 
Among bifidobacteria, B. longum, strains BB536 and SP07/3, B. bifidum MF20/5, B. infantis, 
B. animalis, B. adolescentis and B. breve, have been considered probiotic. Some other bacteria 
and yeasts can also have probiotic properties. These include Enterococcus faecalis, 
Streptococcus thermophilus, Propionibacteria, E. coli Nissle 1917 and yeast Saccharomyces 
boulardii (de Vrese & Schrezenmeir 2008). Probiotics have many potential beneficial health 
effects, which are more or less well documented. The effective use of probiotics for 
significant improvement of lactose digestibility, childhood infectious gastroenteritis, 
diarrhea associated with either antibiotics, rotavirus infection, or chemotherapy, as well as 
traveller’s diarrhea has been well documented (Schrezenmeir & de Vrese, 2001; Walker et 
al., 2006). Probiotics can stimulate humoral or cellular immune systems. They can cause a 
decrease in unfavourable metabolites (e. g. ammonium) in the colon. There are fewer reports 
of other possibilities of the use of probiotics for health improvement, which are limited to a 
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specific probiotic strain, or to a combination of two or more strains (Schrezenmeir & de 
Vrese, 2001; Walker et al., 2006; Thomas & Greer, 2010). 
Due to the implication of intestinal bacteria in the CD, probiotics were also suggested as a 
possible treatment for CD. Among probiotics, Lb. rhamnosus GG, Lb. johnsonii LA1, B. lactis, 
Str. thermophilus, E. coli Nissle 1917 and yeast S. boulardii have been tested for the treatment 
of CD. 
2.1 Mechanism of action 
Several mechanisms by which probiotics exert beneficial effects in treatment of CD have 
been suggested (Boirivant & Strober, 2007; Dharmani & Chadee, 2008; Guandalini, 2010; Ng 
et al., 2009). Probiotics are supposed to improve the epithelial cell barrier function, decrease 
the load of “bad” bacteria by direct or indirect antibacterial effects or exert direct effects on 
epithelial and immune cells by, among other things, affecting their cytokine expression 
profiles. These effects are intertwined to a large extent and the contribution of an individual 
effect is therefore hard to establish. Besides, an individual probiotic bacterium is probably 
not capable of exerting the entire spectrum of activities. Instead, it is more likely to be 
responsible for a specific effect. 
2.1.1 Effects on epithelial cell barrier function 
The layer of epithelial cells that lines the intestinal tract constitutes a physical barrier that 
prevents intestinal bacteria from entering into the organism. The mix of probiotic organisms, 
VSL#3, was able to normalize barrier integrity in IL-10 deficient mice, as shown by the 
measurements of several parameters (conductivity, mannitol flux) on excised tissue 
(Madsen et al., 2001). Barrier function is reinforced by the layer of mucus, which is secreted 
by goblet epithelial cells. It has been shown that some probiotic bacteria are capable of 
modifying the expression of proteins that are involved in mucin production. Lb. plantarum 
299v was able to increase MUC2 and MUC3 mRNA expression in the epithelial cell line 
(Mack et al., 1999), while VSL#3 and E. coli Nissle 1917 increased MUC2, MUC3 and 
MUC5AC protein expression (Otte & Podolsky, 2004). The epithelial layer is also responsible 
for the active transport of nutrients, electrolytes and water. Impaired ability for reabsorption 
of sodium and water from the distal colon leads to diarrhea that usually accompanies CD 
(Zeissig et al., 2007). Str. thermophilus and Lb. acidophilus were able to increase trans-
epithelial resistance, but also alleviate electrolyte transport by increasing chloride secretion 
(Resta-Lenert & Barrett, 2009). Probiotics were also reported to influence the maintenance of 
tight junction proteins by influencing the cytoskeleton architecture. VSL#3 prevented the 
redistribution of tight junction protein ZO-1 (Otte & Podolsky, 2004) and Lb. acidophilus was 
able to prevent the rearrangement of F-actin upon exposure to pathogenic E. coli (Liévin-Le 
Moal et al., 2002). Probiotics can even prevent apoptosis of epithelial cells, as was shown for 
Lb. rhamnosus GG, which was able to activate anti-apoptotic and inhibit pro-apoptotic 
proteins (Yan & Polk, 2002). 
2.1.2 Antibacterial effects 
Probiotics influence the composition of intestinal flora by competing for the available space 
(e. g. available binding sites for adhesion) and for available essential nutrients. They can also 
exert antimicrobial effects by either direct or indirect means. Direct means include 
productions of inhibitory substances like bacteriocins, hydrogen peroxide and organic acids. 
www.intechopen.com
Manipulation of Intestinal Flora as a Way to Treat Crohn's Disease:  
The Role of Probiotics, Prebiotics and Antibiotics  
 
149 
Bacteriocins are diverse group of low molecular weight peptides, usually produced by 
strains from genus Lactobacillus, and by some other lactic acid bacteria, including Lactoccocus 
lactis. Bacteriocins have antimicrobial activity against several bacteria, but are especially 
effective against Gram positive bacteria. Similar substances are produced in probiotic strains 
of Bifidobacteria, and are active against both Gram negative and Gram positive bacteria 
(Guandalini, 2010). Organic acids such as lactic acid, propionic acid and butyric acid are 
produced in fermentative metabolism of probiotics and are responsible for a decrease in pH 
in the gastrointestinal tract, which is harmful to acid sensitive intestinal bacteria. Probiotics 
can also exert indirect antibacterial effects, by stimulating the production of defensins. 
Defensins are human endogenous cationic antimicrobial peptides with antimicrobial activity 
against Gram negative and Gram positive bacteria. They are secreted by specialized 
epithelial Paneth cells. Deficiency in defensins could play an important role in the 
pathogenesis of colonic and ileal CD (Wehkamp et al., 2009). Low expression of ǃ-defensin 
occurs in patients with colonic CD and affects the structure of colonic mucosa. In patients 
with ileal CD, decreased level of Paneth cells ǂ-defensin has been observed and these 
patients also had the NOD2 mutation. These results suggest that there is a connection 
between NOD2 function and expression of ǂ-defensin and that this connection has an 
important implication in the development of ileal CD (Wehkamp et al., 2009). 
2.1.3 Immunomodulative effects on epithelial and immune cells 
Probiotic bacteria can modulate the activity of epithelial and immune cells including 
dendritic cells, monocytes, macrophages, T cells, B cells and NK cells. The immune response 
is mediated by pattern recognition receptors, such as toll-like receptors, which recognize 
specific bacterial features, termed pathogen-associated molecular patterns. These include 
peptidoglycan, lipopolysaccharides, flagellin and DNA variants, such as unmethylated CpG 
motifs. Probiotic bacteria can induce regulatory T cells by stimulating the dendritic cells to 
produce anti-inflammatory cytokines IL-10 and TGFǃ, as was demonstrated with the 
treatment with VSL#3 (Hart et al., 2004) and with several other bifidobacterial strains 
(Young et al., 2004). The activation of regulatory T cells can be initiated by direct binding of 
probiotics to dendritic cells via the DC-SIGN molecule (Smits et al., 2005). This can cause the 
diversion of the immune response toward noninflammatory tolerogenic pattern. Probiotics 
can downregulate the Th1 response by inhibition of the production of proinflammatory 
cytokines by dendritic cells, including the production of IL-12, TNFǂ and IFNǄ. 
Downregulation of the production of TNFǂ was demonstrated in ex vivo treatment of 
intestinal tissue from CD patients with probiotics (Borruel et al., 2002). Probiotics can also 
decrease T cell proliferation and their production of IL-2, IL-4 and IL-10 cytokines, as 
demonstrated with Lb. rhamnosus. This increased T cell hypo-responsiveness was also 
induced in vivo in CD patients and in healthy individuals (Braat et al., 2004). Involvement of 
different mechanisms of action is highlighted by the fact that some strains of lactobacilli not 
only downregulate, but also upregulate the production of IL-12 (Mohamadzadeh et al., 
2005) and switch towards the Th1 response.  
2.2 Clinical trials with probiotics for the treatment of CD 
Probiotics have been tested for their ability to treat CD in several clinical trial settings. Some 
basic data on clinical trials is summarized in Table 1. Some probiotic strains or mixtures of 
strains (E. coli Nissle 1917, S. boulardii, VSL#3, Lb. rhamnosus GG and Lb. johnsonii LA1) were 
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tested in more than one clinical trial. Almost all the trials were designed to be randomized 
and placebo controlled, and more than half were double blind. Four studies were designed 
for the maintenance of remission in CD and five for the prevention of postoperative 
recurrence of CD. One study was designed for the treatment of one of the common extra-
intestinal manifestations of CD, arthralgia, and one for evaluation of the impact of intestinal 
permeability in patients with CD.  
 
Author Year
Probiotics 
and dose 
n Study design
Study 
duration
Study 
purpose 
Outcomes 
Malchow 1997
E. coli Nissle 
1917 
5x1010/day
28 
Randomized, 
placebo 
controlled, 
single center
12 
months
Maintenance 
of remission 
of colonic CD
Better outcome 
in probiotic 
group, not 
significant 
Guslandi 2000
S. boulardii 
1g/day 
32 
Randomized, 
single center
6 
months
Maintenance 
of remission 
of CD 
Significant 
difference 
between 
probiotic and 
mesalazine 
group 
Campieri 2000
VSL#3 
6g/day + 
rifaximin 
1,8 g/day 
40 
Randomized, 
controlled 
12 
months
Prevention of 
postoperative 
recurrence of 
CD 
Efficacy of 
combination of 
antibiotic and 
probiotic 
Prantera 2002
Lb. 
rhamnosus 
GG 
12x109 
CFU/day 
45 
Randomized, 
double blind, 
placebo 
controlled, 
single center
12 
months
Prevention of 
recurrence of 
CD after 
surgery 
No difference 
Schultz 2004
Lb. 
rhamnosus 
GG 
2x109 
CFU/day 
11 
Randomized, 
double blind, 
placebo 
controlled, 
single center
6 
months
Maintenance 
of remission 
of CD 
No difference, 
small number 
of patients 
Bousvaros 2005
Lb. 
rhamnosus 
GG 
2x109 
CFU/day +
295 mg 
inulin/day
75 
Randomized, 
double blind, 
placebo 
controlled, 
multicenter 
24 
months
Maintenance 
of remission 
of CD in 
children 
No difference 
Karimi 2005
VSL#3 
450 bilion 
bacteria 
twice a day
29 
Open 
labeled, pilot 
study 
3 
months
Treatment of 
arthralgia in 
patients with 
ulcerative 
colitis and 
CD 
Significant 
improvement 
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Marteau 2006
Lb. johnsonii 
LA1 
2x109 CFU 
twice a day
98 
Randomized, 
double blind, 
placebo 
controlled, 
multicenter 
6 
months
Prevention of 
postoperative 
recurrence of 
CD 
No difference 
Van 
Gossum 
2007
Lb. johnsonii 
LA1 
1x1010 
CFU/day 
70 
Randomized, 
double blind, 
placebo 
controlled, 
multicenter 
3 
months
Prevention of 
postoperative 
recurrence of 
CD 
No difference 
Garcia 
Vilela 
2008 S. boulardii 34 
Randomized, 
placebo 
controlled 
3 
months
Influence on 
intestinal 
permeability 
of patients 
with CD 
Improvement 
of intestinal 
permeability 
Madsen 2008
VSL#3 
900 billion 
bacteria 
twice a day
120
Randomized, 
double blind, 
placebo 
controlled, 
multicenter 
3 
months
Prevention of 
postoperative 
recurrence of 
CD 
Less 
endoscopic 
recurrence 
comparing to 
placebo 
Table 1. Clinical studies investigating the effects of probiotics in the maintenance of 
remission in CD or in the prevention of postoperative recurrence of CD (adapted from 
(Isaacs & Herfarth, 2008)). 
For maintenance of remission of the CD, 28 patients with active colonic CD were treated 
with synthetic corticosteroid prednisone and non-pathogenic probiotic E. coli strain Nissle 
1917, or with placebo (Malchow, 1997). From the results of remission rate we can conclude 
that a similar proportion of patients entered in remission in the two groups. More patients 
from the placebo group (63.6%) had relapse, when compared with the probiotic group, in 
which 33.3% of patients relapsed after 12 months of treatment. Even though these results 
were not statistically significant, a better outcome was reached in the probiotic group, which 
indicated some beneficial effect of E. coli Nissle 1917 on the maintenance of remission in 
colonic CD. Because of the small number of participants in this study, the authors suggested 
that larger study should be performed.  
Guslandi et al. investigated possible therapeutic benefits of non-pathogenic yeast S. boulardii 
in the maintenance of remission in CD (Guslandi et al., 2000). In this study, 32 patients with 
CD in clinical remission were divided randomly into two groups. The first group was 
treated with mesalamine two times a day and with S. boulardii once a day. The second group 
was treated only with mesalamine three times a day. The study was ended after 6 months of 
treatment. In the mesalamine group, 6 of 16 (37.5%) patients had clinical relapse after 6 
months while, in the group treated with mesalamine and S. boulardi, only 1 patient in 16 
(6.25%) had clinical relapse. This difference is statistically significant and demonstrates that 
S. boulardii, in combination with anti-inflammatory drug, could have beneficial effects in the 
maintenance of remission in CD. 
The efficacy of S. boulardii in the treatment of CD was again evaluated in a study of the 
influence of S. boulardii on intestinal permeability in patients with CD in remission (Garcia 
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Vilela et al., 2008). The study was carried out on 34 patients who received either placebo or 
S. boulardii for 3 months. Additionally, patients received standard therapy with 
corticosteroids, anti-inflammatory drugs or antibiotics. Intestinal permeability was 
evaluated by measuring lactulose/mannitol ratio. The ratio was 0.005 +/- 0.0037 in healthy 
volunteers, and 0.021 +/- 0.01 in patients with CD. After 3 months of treatment, 
lactulose/mannitol ratio increased by 0.004 +/- 0.010 in the placebo group and decreased by 
0.008 +/- 0.006 in the S. boulardii group. These results demonstrated that S. boulardii, in 
combination with standard therapy for CD, could improve intestinal integrity in patients 
with CD. 
Probiotic Lb. rhamnosus GG was also tested for the ability to maintain the remission of CD 
(Schultz et al., 2004). Probiotic therapy with Lb. rhamnosus GG was tested in eleven patients 
with moderate to active CD. Patients were first treated with antibiotics for two weeks, 
followed by probiotic therapy for 6 months. Relapse occurred in 2 of 5 patients in the 
probiotic group, as well as in 2 of 6 patients in the placebo group. Two patients from each 
group achieved and maintained remission. No difference between probiotic and placebo 
group was thus observed and no benefit of Lb. rhamnosus GG could be reported. Small 
sample size was suggested as a reason why no difference was observed. 
More than 70% of CD patients will undergo at least one surgery in their life, and recurrence 
of CD in patients after surgical intestinal resection is very common (Marteau et al., 2006). 
Endoscopic recurrence of CD in patients is usually observed within one year after surgery 
and is followed by clinical recurrence. Around one quarter of patients will require further 
surgery in the following years, if no postoperative treatment of the disease will take place 
(Doherty et al., 2009). Prevention of postoperative CD is therefore another important target 
of probiotic treatment. This approach was first tested with probiotic mixture VSL#3 in 
combination with antibiotic rifaximin in a randomized controlled clinical trial with 28 
patients (Campieri et al., 2000). Half of the patients received rifaximin dose for the first three 
months, which was followed by probiotic dose for the next 9 months. The control group 
received 4 g of mesalamine per day for 12 months. Probiotic mixture VSL#3 contains 4 
strains of lactobacilli, 3 strains of bifidobacteria and Str. thermophilus. No side effects were 
reported during the study. At the end of the treatment, 4 of 20 patients had endoscopic 
recurrence, while in the placebo group, 8 patients had endoscopic recurrence. The authors 
concluded that the combination of VSL#3 and rifaximin is effective in preventing 
postoperative endoscopic recurrence of CD. The effectiveness of probiotic mixture VSL#3 
alone in preventing postoperative recurrence of CD was later confirmed in a larger 
randomized, double blind, placebo controlled multicenter study on 120 patients (Madsen et 
al., 2008). Patients receiving VSL#3 for 3 months showed less endoscopic recurrence (9,3% of 
patients) compared with placebo group (15,7% recurrence). Results were substantiated with 
measurements of mucosal pro-inflammatory cytokine levels. 
Beside VSL#3, which is a mixture of probiotic strains, some Lactobacillus strains were tested 
by themselves for the ability to prevent postoperative recurrence of CD. Probiotic strain 
Lactobacillus rhamnosus GG was tested for prevention of postoperative recurrence in a 
randomized double blind and placebo controlled study (Prantera et al., 2002). 23 patients 
received Lb. rhamnosus GG and 22 received placebo daily for one year. No side effects were 
reported, however 13 patients, from the two groups, did not finish the study. At the end of 
the study, 15 patients from Lb. rhamnosus GG group and 17 patients from the placebo group 
showed clinical remission. Among the patients with clinical remission, 9 of 15 patients in the 
probiotic group, and 6 of 17 patients in the placebo group had endoscopic recurrence of CD. 
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Clinical recurrence was observed in 3 patients from the Lactobacillus GG group and in two 
from the placebo group. No benefit of Lactobacillus rhamnosus GG in the postoperative 
treatment of CD could thus be observed. It was suggested that the study should be 
considered as a pilot one because of small number of patients, different demographic and 
different disease background. 
Lb. johnsonii LA1 is another Lactobacillus strain that was used in clinical trials for the prevention 
of postoperative CD. The first double blind, placebo controlled clinical trial with Lb. johnsonii 
LA1 was reported in 2006 (Marteau et al., 2006). 98 patients that underwent ileocolonic, colonic 
or ileal CD surgery were involved. Patients were administered 2x109 colony forming units 
(CFU) Lb. johnsonii LA1 or placebo twice a day for 6 months. Endoscopic recurrence was 
observed in 49% of patients in the probiotic group and in 64% of patients in the placebo group. 
Clinical recurrence was noted in four patients in the probiotic group and in three in the 
placebo group. Results were not statistically significant and beneficial effects of Lb. johnsonii 
LA1 on postoperative recurrence in patients with CD could not be established. 
A second clinical trial of the effectiveness of probiotic Lb. johnsonii LA1 in preventing 
endoscopic postoperative recurrence of CD was conducted with 70 patients that underwent 
curative ileo-caecal resection (Van Gossum et al., 2007). Clinical trial was designed as a 
randomized, double blind, placebo controlled multicenter study. Patients were treated 
either with 1x1010 CFU Lb. johnsonii LA1 daily or with placebo for 12 weeks. No difference in 
measured parameters or in clinical relapse between placebo group and Lb. johnsonii group 
was observed. Clinical relapse was observed in 4 patients in Lb. johnsonii group and in 2 
patients in the placebo group after 12 weeks of treatment.  
Some limited research has also been done on the use of probiotics in pediatric CD. A small 
pilot study was conducted with Lb. rhamnosus GG in children with active CD (Gupta et al., 
2000). Four patients were involved in the study, two with ileocolonic CD and two with 
gastrocolonic CD. Report has shown significant improvement after treatment with 1010 CFU 
of probiotic. Patients were also receiving standard therapy for CD. This study was later 
followed by a randomized, double blind, placebo controlled trial with Lb. rhamnosus GG 
strain which was given in addition to standard therapy for the maintenance of remission in 
children with CD (Bousvaros et al., 2005). 75 children with CD in remission were involved in 
the study for the period of two years. Results of the study have shown no significant 
difference between probiotic and placebo group in the time of relapse of CD. These results 
substantiated the results of a previous study on adults which also showed the 
ineffectiveness of Lb. rhamnosus GG in maintaining remission in CD. Because the 
effectiveness of probiotics in the treatment of CD was not established, treatment of CD with 
probiotics is not recommended for children (Thomas & Greer, 2010).  
Extra-intestinal manifestations like arthralgia and arthritis are common complications of 
CD. They are reported to occur in 10-35% of patients. Since beneficial effects of probiotics 
were observed in the treatment of ulcerative colitis and sometimes of CD, the treatment of 
arthralgia with probiotics mixture VSL#3 was also suggested (Karimi et al., 2005). Of 29 
patients with IBD involved in the study, only 16 patients ended the 3 months study and 9 of 
them were CD patients. After three months of treatment, the status of arthralgia differed 
between patients with peripheral arthralgia and axial arthralgia. Only patients with 
peripheral arthralgia reported improvements in their general well being and joint 
complaints. There was no relapse reported in patients after 3 months of treatment. The 
results of the study were shown for all IBD patients together. The results for patients with 
CD therefore cannot be discerned from those of patients with ulcerative colitis. From that it 
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can only be concluded that probiotic mixture VSL#3 had beneficial effects on arthralgia in 
patients with IBD, and possibly also in the subgroup of patients with CD. 
2.3 Recombinant probiotic bacteria for the treatment of CD 
Health effects of probiotic bacteria can be strengthened by genetic engineering which 
enables incorporation of new, defined traits into the existing bacterial repertoire. 
Recombinant bacteria can be used as a vector for the delivery of therapeutic proteins to the 
intestinal mucosa. Potential synergistic effects between existing probiotic and introduced 
therapeutic properties can be envisaged. Genetically modified probiotics will enable the 
selection of the desired protein, selection of the localization of protein expression 
(intracellular, secreted) and selection of the conditions required for the induction of the 
expression. It may also be possible to obtain a long term effect with colonizing strains 
(Marteau et al., 2009). 
To date, the focus has been on lactic acid bacterium Lactococcus lactis. It does not have a 
probiotic status and does not colonize the intestine, but is well studied and is readily 
amenable for genetic modification. L. lactis strains with the ability to produce anti-
inflammatory cytokine IL-10 or to bind pro-inflammatory cytokine TNFǂ have been 
constructed.  
Genetically modified L. lactis secreting cytokine IL-10 was engineered and tested in two 
murine colitis mouse models (Steidler et al., 2000). Results of intragastric administration of 
L. lactis secreting IL-10 showed 50% reduction in DSS-induced colitis and prevention of 
colitis in IL-10 knockout mice. In further research, the authors presented genetically 
modified L. lactis, which was engineered by replacing the thymidylate synthase gene thyA 
with synthetic human IL-10 gene (Steidler et al., 2003). This recombinant bacterium (LL-
Thy12) was able to produce human IL-10 and was not able to survive in the environment 
without thymidine or thymine. This enabled the biological containment of the bacterium 
and markedly decreased the safety concerns. Such a strain is appropriate for human use and 
the effectiveness of LL-Thy12 was investigated in a phase I trial on patients with CD (Braat et 
al., 2006). Results of the trial have demonstrated safety of the strain. Only minor adverse 
effects were noted and some beneficial effects on the disease activity were observed.  
Two recent studies have introduced another approach for the treatment of intestinal 
inflammations by binding the pro-inflammatory cytokine TNFǂ. The first study used 
engineered L. lactis which secreted TNFǂ-neutralizing nanobody (camelid heavy chain 
fragment). Its efficacy was demonstrated in two mouse models of colitis (Vandenbroucke et 
al., 2010). In another study, different binding TNFǂ-binding molecule was applied. TNFǂ-
binding affibody was expressed and immobilized on the surface of engineered L. lactis 
(Ravnikar et al., 2010).  
As noted earlier, besides IL-10, transforming growth factor beta (TGFǃ) has often been 
described as an anti-inflammatory cytokine in CD. Commensal gut Gram-negative 
bacterium Bact. ovatus was engineered to express TGFǃ1 under the control of xylan. Xylan is 
a dietary fiber which is important for the safety of this system. Results of the study have 
shown significant improvement of acute colitis in mice (Hamady et al., 2010).  
Initial studies of the concept of recombinant probiotic bacteria have shown promising 
results, but were mostly obtained in the animal studies of the treatment of ulcerative colitis. 
Further research will show whether recombinant probiotics have the capacity to be 
considered as an alternative in the treatment of CD.  
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3. Prebiotics 
Prebiotics were first defined by Gibson and Roberfroid as “nondigestible food ingredients 
that beneficially affect the host by selectively stimulating the growth and/or activity of one 
or a limited number of bacteria in the colon and thus improve host health” (Gibson & 
Roberfroid, 1995). An updated definition of probiotics was later suggested as follows: “A 
prebiotic is a selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity of the gastrointestinal microflora, that confers benefits upon 
host wellbeing and health” (Gibson et al., 2004). In the past, many food ingredients were 
classified as potential prebiotics. However, in sensu stricto, the following criteria have to be 
fulfilled for a substance to be classified as prebiotic (Gibson et al., 2004):  
 resistance to gastric acidity, to hydrolysis by mammalian enzymes and to 
gastrointestinal absorption; 
 fermentability by intestinal microflora; 
 selective stimulation of the growth and/or activity of intestinal bacteria associated with 
health and wellbeing. 
These criteria are fulfilled by only three food ingredients that were marked as prebiotics: 
fructo-oligosaccharides (inulin and oligofructose), transgalacto-oligosaccharides and 
lactulose. All three prebiotics are carbohydrates; however, according to the definition, non-
carbohydrates can also be classified as prebiotics. According to other authors, even the 
prebiotic status of lactulose can be opposed, because the first criterion for prebiotic 
classification is not totally fulfilled (Roberfroid, 2007). Nevertheless, lactulose prebiotic 
status is substantiated by a lot of data from human studies. Other carbohydrates that are 
good candidates for prebiotics are isomalto-oligosaccharides, lactosucrose, xylo-
oligosaccharides, soybean oligosaccharides and gluco-oligosaccharides (Gibson et al., 2004; 
Roberfroid, 2007). These are already considered as probiotics by some authors.  
Fructo-oligosaccharides, which are represented by inulin and oligofructose, occur in nature 
in different plants, such as chicory, leek, onion, garlic, and asparagus (Leenen & Dieleman, 
2007). In 2006, results of a small study on clinical, immunological and microbiological effects 
of fructo-oligosaccharides in patients with active CD were published (Lindsay et al., 2006). 
In this study, 10 patients with active ileocolonic CD were treated with 15 g of fructo-
oligosaccharides per day for 21 days. The results of the study showed that prebiotics 
oligofructose and inulin have beneficial effects on the activity of CD. This was demonstrated 
by increased intestinal bifidobacterial content and by enhanced expression of IL-10 and 
TLRs in dendritic cells. The authors suggested further investigation of immunological and 
microbiological effects of these prebiotics, and a larger randomized double-blind placebo-
controlled trial was indeed published in 2011. 103 patients with active CD were enrolled. 
They received 15 g of fructo-oligosaccharides or placebo per day in a period of 4 weeks 
(Benjamin et al., 2011). No significant differences in faecal bifidobacteria concentration 
between the placebo and prebiotic groups after 28 day of prebiotic treatment could be 
observed and no clinical benefits could be recorded. The results of the pilot study therefore 
could not be reproduced in the larger setting.  
The use of prebiotics is usually focused on stimulation of the growth or activity of 
bifidobacteria and lactobacilli because of their well known beneficial health effects. For that 
reason, probiotics and prebiotics are often used together in the treatment of active CD and 
other gastrointestinal disorders. The product that contains both probiotics and prebiotics is 
called synbiotic. An example of a synbiotic is Synbiotic 2000, which was used in a small, 
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multicenter, randomized, double-blind, placebo-controlled study to prevent postoperative 
recurrence of CD (Chermesh et al., 2007). Synbiotic 2000 is composed of 4 probiotics (1010 
Pediacoccus pentoseceus, 1010 Lb. raffinolactis, 1010 Lb. paracasei subsp. paracasei 19, and 1010 Lb. 
plantarum 2362) and 4 prebiotics (2.5 g ǃ-glucans, 2.5 g inulin, 2.5 g pectin and 2.5 g resistant 
starch). The clinical trial involved 30 patients with CD who were treated, after surgery, 
either with Synbiotic 2000 or with placebo once a day for up to 24 months. Only 9 patients 
completed the study, 7 from Synbiotic 2000 group and 2 from placebo group. No difference 
between the two groups in clinical, laboratory and endoscopic results could be confirmed 
and it was concluded that Synbiotic 2000 is not effective in preventing postsurgical 
recurrence of CD (Chermesh et al., 2007). Because of relatively small group of patients 
involved in this clinical trial more research was suggested, involving a larger setup and 
different synbiotic mixtures.  
Another synbiotic therapy was reported in a clinical trial with 35 patients with active CD 
(Steed et al., 2010). The synbiotic product in this instance contained 2x1011 CFU of probiotic 
bacterium B. longum and 6 g of prebiotic Synergy 1, which is the commercial name for 
oligofructose-enriched inulin. Patients had received synbiotic or placebo twice a day for six 
months. Treatment with synbiotic improved clinical symptoms and histological score in 
treated patients with active CD. A significant reduction of TNFǂ expression in patient 
treated with synbiotic was observed after three months, however after six months, the 
reduction was no longer significant. A beneficial effect of synbiotic could also be observed in 
the significant increase of the level of bifidobacteria in treated patients.   
4. Antibiotics 
The use of antibiotics in the primary treatment of CD is again based on the theory of 
involvement of bacteria in the pathogenesis of the disease (Lal & Steinhart, 2006). CD could 
be caused by an aggressive immune response to antigens in the gut of genetically 
susceptible individuals (Prantera, 2009). Antibiotics in CD have been used for the 
nonspecific reduction of intestinal bacterial load. In clinical trials, several antibiotics were 
used for the treatment of CD (Prantera, 2009): 
 antibiotics with antimycobacterial activity (clofazimin, clarithromycin, rifabutin) 
 metronidazole (active against anaerobic bacteria) 
 ciprofloxacin (active against E. coli)  
 rifaximin.  
Antibiotics have shown some effectiveness in the treatment of CD, mostly in reducing post-
operative recurrence of CD. Their benefits however have to be balanced by the side effects 
they cause (Doherty et al., 2010).  
4.1 Antimycobacterial therapy 
The earlier described single pathogen hypothesis suggests M. avium subsp. paratuberculosis 
as a causative agent for CD. For that reason, antibiotics against mycobacteria have been 
tested in the treatment of CD. In 2007, a prospective, parallel, placebo-controlled, double-
blind, randomized clinical trial in patients with active CD was reported. The authors used 
the combination of clarithromycin, rifabutin, and clofazimine for two years (Selby et al., 
2007). They concluded that this combination of antibiotics against M. paratuberculosis 
showed no benefits in the treatment of CD. This could serve as another piece of evidence 
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against the single pathogen hypothesis with M. avium subsp. paratubercolosis. Nevertheless, 
further studies should be performed to confirm or disprove these findings. 
4.2 Metronidazole and ciprofloxacin 
Metronidazole and ciprofloxacin are the most popular antimicrobial drugs used in the 
treatment of CD. They exert antimicrobial activity against Gram negative and Gram positive 
bacteria (Dharmani & Chadee, 2008). Metronidazole is a nitromidazole antibiotic, and 
ciprofloxacin belongs to a group of fluoroquinolone antibiotics. Both antibiotics, alone or in 
combination, were used in several clinical trials for active CD treatment. Antibiotics have 
been effective in preventing the remission of CD; however their benefits have to be balanced 
by the side effects they cause.  One of the reports describes the use of a combination of 
metronidazole and ciprofloxacin therapy in patients with active ileal or colonic CD. The 
therapy was well tolerated and showed beneficial effects with symptomatic improvement in 
patients with active CD, especially in the colon (Greenbloom et al., 1998). Only five of 72 
patients required withdrawal of the therapy because of side effects. The authors speculated 
that only metronidazole is to be held responsible for side effects (e. g. neuropathy, nausea 
and anorexia), as those have already been reported in previous studies on metronidazole 
treatment of CD (Greenbloom et al., 1998; Prantera et al., 1996). 
4.3 Rifaximin 
Rifaximin is a rifamycin-based antibiotic with a broad spectrum of antimicrobial activity. 
This covers Gram positive and Gram negative bacteria, and includes both aerobic and 
anaerobic bacteria. Rifaximin is poorly absorbed from the gastrointestinal tract and therefore 
has less systemic effects. It has an excellent safety profile, minimal drug interaction, and 
negligible impact on the intestinal microbiome. For those reasons, it has a great potential in 
the treatment of gastrointestinal diseases, including active CD. Rifaximin is approved in 
more than 30 countries for a variety of gastrointestinal disorders, including the treatment of 
traveler’s diarrhea, caused by noninvasive diarreagenic E. coli (Koo & DuPont, 2010).  
In recent years, several studies have reported rifaximin effectiveness in the treatment of CD. 
In 2006, a multicenter, double blind, randomized, placebo-controlled study was reported. 
Rifaximin gastroresistant granules (800 mg once a day or 800 mg twice a day) were given 
orally to 83 patients with mildly to moderately active CD for 12 weeks (Prantera et al., 2006). 
Rifaximin gastroresistant granules were designed specifically for CD treatment. They were 
coated with a co-polymer, which was designed to by-pass the stomach and dissolve in the 
duodenum-jejunum, thereby concentrating the active rifaximin in the small intestine. In the 
study, the clinical remission was achieved in 52% of the group who received rifaximin twice 
a day, in 32% of the group who received rifaximin once a day, and in 33% of the group who 
received a placebo dose twice a day. In comparison to the placebo group, the rifaximin 
group was superior in inducing clinical remission of mildly to moderately active CD, 
although the difference was not statistically significant. Nevertheless, the results were 
encouraging and a larger randomized placebo-controlled study is justified.  
In 2008, Shafran and Burgunder reported the treatment of five patients with newly 
diagnosed mild CD with 400 mg rifaximin dose twice daily for 3 months. This was the 
patients’ first therapy without prior biologic or immunomodulatory treatment. The therapy 
was successful in 3 patients and substantial endoscopic and clinical improvements were 
observed. The authors suggested that rifaximin therapy could be an effective first-line 
treatment in patients with small intestinal CD (Shafran & Burgunder, 2008).  
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The same authors performed a retrospective analysis of 68 patients with CD, who were 
treated with rifaximin between 2001 and 2005. Patients had CD localized to the small or 
large intestine, and 56% of patients had previously undergone surgery. Most of the patients 
were treated with rifaximin dose 600 mg/day. Almost half of them were also receiving 
steroids, and some of them were also treated with anti-inflammatory agents, biologics (e.g. 
infliximab), antidiarrheal agents, and immunomodulators. The retrospective analysis 
showed that clinical remission was achieved in 65% of the patients with CD. Interestingly, 
this percentage was a little higher in patients who were not treated with steroids. Among 
the patients who received only rifaximin therapy, 67% achieved remission. These findings 
again substantiate the use of rifaximin alone for the induction of remission in CD (Shafran & 
Burgunder, 2010). 
Several studies on the efficacy of rifaximin in CD have shown that it has a good potential in 
CD therapy, either as a first or second line treatment. Nevertheless, further research of 
rifaximin efficacy in patients with CD is required. Among other things, its precise 
mechanism of action in CD should be clarified. 
4.4 Antibiotics in the prevention of post-operative CD 
Antibiotics are most frequently applied for the prevention of post-operative recurrence of 
CD (Doherty et al., 2009; Doherty et al., 2010; Lal & Steinhart, 2006). Rutgeerts and co-
workers published two double-blind randomized studies of the efficacy of nitroimidazole 
antibiotics in the prevention of postoperative CD (Rutgeerts et al., 2005; Rutgeerts et al., 
1995). In the first study, one week after resection surgery, 30 patients started to receive 
antibiotic metronidazole at a dose of 20 mg/kg body weight once a day for a period of three 
months (Rutgeerts et al., 1995). Another 30 patients received placebo. Nine patients did not 
finish the study, two in the placebo group and seven in metronidazole group. The reasons 
for the latter patients were gastrointestinal intolerance, acute paranoia, polyneuropathy, 
suture leak, and the lack of compliance. After the end of the therapy, patients were observed 
every 6 month for the period of three years. After a 3 month therapy, 21 of 28 (75%) patients 
in the placebo group had recurrent lesion in neoterminal ileum, while this only happened to 
12 of 23 (52%) patients in the metronidazole group. Metronidazole significantly reduced 
endoscopic recurrence, which was observed in 3 of 23 (13%) patients in metronidazole 
group and in 12 of 28 (43%) patients in the placebo group. Statistically significant reduction 
of clinical recurrence was observed only after one year. The reduction was no longer 
significant two and three years after surgery, but the benefit of metronidazole treatment was 
still present. This study showed that metronidazole was effective in preventing early severe 
recurrence of CD. However, several side effects occurred in the metronidazole group, 
including gastrointestinal intolerance, metallic taste, leucopenia, paraesthesias of the limbs, 
abnormal liver function, polyneuropathy, and psychosis. Because of high rates of adverse 
effects with metronidazole, a second study for the prevention of postoperative CD was 
performed with antibiotic ornidazole (Rutgeerts et al., 2005). Ornidazole is also a 
nitroimidazole antibiotic, but supposedly causes fewer side effects than metronidazole. 80 
patients after ileocolonic resection were included. Half of the patients received 500 mg of 
ornidazole twice daily and half received a placebo for 12 months. After the end of the 
treatment, clinical recurrence manifested in 3 of 38 (7.8%) patients in the ornidazol group 
and in 15 of 40 (37.5%) patients in the placebo group. Additionally, the results of clinical 
recurrence were measured two and three years after surgery. After two years, 11 of 37 
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(29.7%) patients had clinical recurrence in the ornidazol group, and 18 of 40 (45%) patients 
in placebo group. After 3 years, 17 of 37 (45.9%) patients had clinical recurrence in the 
ornidazol group and 19 of 40 (45.5%) patients in the placebo group. Similar to metronidazol, 
ornidazol has shown efficacy in preventing postoperative clinical recurrence of CD, but has 
also caused numerous side effects. To alleviate these, the authors suggested the use of a 
smaller dose (500 mg/day) of ornidazol in postoperative therapy of CD. 
When antibiotics are used for preventing postoperative recurrence of CD, they are often 
combined with other therapies for CD, including immunomodulators, probiotics, steroids, 
and others. The studies of combinations of antibiotics with probiotics were presented in the 
Chapter 2.2. The combination of antibiotic metronidazole and immunomodulator 
azathioprine was studied in a placebo-controlled randomized trial to prevent postoperative 
recurrence of CD (D'Haens et al., 2008). It was performed on 81 CD patients after curative 
ileal or ileocolonic resection. The first group of 40 patients received 500 mg metronidazole 
three times per day and 100-150 mg azathioprine once per day for a period of three months. 
The second group of 41 patients received metronidazole without azathioprine. After three 
months, the metronidazole treatment was discontinued, but the study continued for another 
nine months with azathioprine treatment only (the first group received azathioprine and the 
second group placebo). 32 patients from the first group and 29 patients from the placebo 
group reached the end of the study. Endoscopic recurrence was measured three and twelve 
months after the beginning of the study. After 3 months, significant endoscopic recurrence 
occurred in 12 of 35 (34.3%) patients in the first group, and in 20 of 38 (52.6%) patients in the 
placebo group. After twelve months, significant endoscopic recurrence occurred in 14 of 32 
(43.7%) patients in the first group and in 20 of 29 (69%) patients in the placebo group. Also 
after twelve months, inflammatory lesions were not observed in seven patients in the first 
group and only in one patient in the placebo group. There was no clinical recurrence in 
patients after three months of surgery. Twelve months after surgery, 10 clinical recurrences 
were observed, three in the first group and seven in the placebo group. Some adverse effects 
occurred in both groups, but overall the treatment was well tolerated. It can be concluded 
that the combination of antibiotic with immunomodulator is superior to antibiotic alone in 
preventing postoperative recurrence of CD. Because of the shorter period of antibiotic 
treatment, the number of side effects in patients was lower than in previous studies. 
Nevertheless, further studies on larger number of patients are needed to support this 
approach.  
5. Conclusion 
Human intestinal bacteria are an important factor in human health, as well as in the 
pathogenesis of intestinal disorders, including CD. However, none of the proposed 
mechanisms of action can alone sufficiently explain the disease occurrence. Bacterial 
components are undoubtedly involved in the activation of abnormal autoimmune responses 
which further trigger the disease symptoms. The whole picture is however more complex 
with more active bacterial involvement.  
Probiotics are an obvious choice for influencing the intestinal microbiome. Probiotics have 
shown some promising initial results in the treatment of CD. However, in general, they 
were not found to be superior to placebo in increasing the time of remission of CD or 
reducing post-operative recurrence in controlled clinical trials. Two notable exceptions 
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preserve hope for probiotics in the treatment of CD. Yeast S. boulardii was shown to be more 
effective than melsalazine in maintaining remission of CD (Guslandi et al., 2000) and 
improving intestinal permeability in CD patients (Van Gossum et al., 2007). Probiotic 
mixture VSL#3 was successful in the treatment of CD-induced arthralgia (Karimi et al., 
2005) and in the prevention of postoperative recurrence of CD (Madsen et al., 2008). These 
studies offer support for the commonly asserted claim that further trials are justified. 
There are several reasons that could explain the failure of other clinical trials and speak in 
favor of probiotics. The overall number of clinical trials is low, as well as the number of 
participants. Trials were designed in different ways, had different goals and measured 
different outcomes. Despite the abundance of bacteria with attributed probiotic properties, 
just a few were used in clinical trials. Additionally, there were differences in doses and 
regimens. Future trials should broaden the spectrum of probiotic bacteria in the treatment. 
Probiotics are not alike and exert effects by different mechanisms. The growing number of 
probiotic bacteria, however, clearly prevents systematic testing of all of them. To overcome 
this difficulty two strategies can be foreseen.  
The first includes testing of larger combinations of bacterial strains. Individual bacteria in 
the mixture would have different effects and could well act synergistically. This view can be 
supported by the success of probiotic mixture VSL#3 relative to individual bacteria Lb. 
rhamnosus GG and Lb. johnsonii LA1. The ultimate example of that approach would be a fecal 
transplant from healthy donors to patients. This has been successfully applied in the 
treatment of C. difficile infection. It was also shown that the changes in the composition of a 
recipient’s intestinal flora were long-lasting. Recipients’ intestinal flora resembled the 
composition of the donor’s flora even after 24 weeks (Grehan et al., 2010). This approach is 
not without risks, as transfer of potential pathogens is difficult to exclude.  
The second approach would necessitate better understanding of the disease etiology and 
modes of action of various bacteria. This would require the use of better animal models of 
CD. The majority of the studies in mice were performed on models of intestinal 
inflammation which resemble that of ulcerative colitis, with inflammatory changes limited 
to the colon. Inflammation was achieved with chemicals or genetic knock-out, which only 
weakly reflect the origin and course of CD in humans. Two mouse models of CD have been 
described, TNF ΔARE and SAMP1/YitFc (Pizarro et al., 2003). They should be applied in the 
search of a single probiotic strain with the desired properties. 
Recombinant probiotics have reasonable potential for the treatment of CD in the future. 
They combine the safety of probiotics with a defined mechanism of action. However, 
solution of the remaining safety concerns and further human clinical trials will be needed 
before they can be recommended. 
Antibiotics constitute the most straightforward approach for interfering with the intestinal 
microbiome by lowering the bacterial content in a mostly unspecific fashion. The approach 
has shown clinical efficacy, but at a price of quite severe adverse effects. Rifaximin could 
assume greater importance in the future since it is a poorly absorbed, broad-spectrum 
antibiotic with fewer side effects. 
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